<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
As 2021 winds down, investors may want to keep an eye on several drug companies that hope to get key approvals from the Food and Drug Administration before the year is out. Among the pharmas hoping to get their treatments green-lighted are Argenx SE ( ARGX , Financial), Calliditas Therapeutics AB ( CALT , Financial), Merck & Co. Inc. ( MRK , Financial) and Novartis ( NVS , Financial).
...read full article on GuruFocus
